The Failure of Solanezumab — How the FDA Saved Taxpayers Billions
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The failure of solanezumab offers a window into the U.S. drug regulatory system, particularly in the context of the 21st Century Cures Act and the national debate about the role of the FDA. The solanezumab story is an important case of a regulatory system that worked.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the expedition3 trial (NCT01900665), aimed at further validating the drug’s efficacy in patients with mild AD, the drug was declared unsuccessful in 2016, as it failed to meet its primary endpoints.457–459”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [457]
Citations
Cites
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
Kazi, D. S., Moran, A. E., Coxson, P. G., Penko, J., Ollendorf, D. A., Pearson, S. D., Tice, J. A., Guzman, D., & Bibbins-Domingo, K. (2016) · JAMA · doi:10.1001/jama.2016.11004 · Cited by 382
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Park, J.-H., Ju, Y. H., Choi, J. W., Song, H. J., Jang, B. K., Woo, J., Chun, H., Kim, H. J., Shin, S. J., Yarishkin, O., et al. (2019) · Science Advances · doi:10.1126/sciadv.aav0316 · Cited by 216
Can an Infection Hypothesis Explain the Beta Amyloid Hypothesis of Alzheimer’s Disease?
Fulop, T., Witkowski, J. M., Bourgade, K., Khalil, A., Zerif, E., Larbi, A., Hirokawa, K., Pawelec, G., Bocti, C., Lacombe, G., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00224 · Cited by 198
Role of the peripheral innate immune system in the development of Alzheimer's disease
Le Page, A., Dupuis, G., Frost, E. H., Larbi, A., Pawelec, G., Witkowski, J. M., & Fulop, T. (2018) · Experimental Gerontology · doi:10.1016/j.exger.2017.12.019 · Cited by 157
“A number of recently published reports have suggested alternative causes of AD because all clinical studies that have attempted to modulate the concentration of Aβ in the brain have failed to show any significant clinical benefit (Mehta et al., 2017; Sacks et al., 2017).”
Alzheimer’s disease as oligomeropathy
Ono, K. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2017.08.010 · Cited by 129
Yokoi, T., Watanabe, H., Yamaguchi, H., Bagarinao, E., Masuda, M., Imai, K., Ogura, A., Ohdake, R., Kawabata, K., Hara, K., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00304 · Cited by 116
Staffaroni, A., Elahi, F., McDermott, D., Marton, K., Karageorgiou, E., Sacco, S., Paoletti, M., Caverzasi, E., Hess, C., Rosen, H., et al. (2017) · Seminars in Neurology · doi:10.1055/s-0037-1608808 · Cited by 91
Metabolic Dysfunction in Alzheimer’s Disease: From Basic Neurobiology to Clinical Approaches
Clarke, J. R., Ribeiro, F. C., Frozza, R. L., De Felice, F. G., & Lourenco, M. V. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179911 · Cited by 87
“For instance, the anti-A (cid:2) antibody solanezumab failed in a large clinical trial tracking more than 2,100 people diagnosed with mild dementia due to AD for 18 months [15].”
Munawara, U., Catanzaro, M., Xu, W., Tan, C., Hirokawa, K., Bosco, N., Dumoulin, D., Khalil, A., Larbi, A., Lévesque, S., et al. (2021) · Immunity & Ageing · doi:10.1186/s12979-021-00236-x · Cited by 74
The Role of Genetics in Advancing Precision Medicine for Alzheimer’s Disease—A Narrative Review
Freudenberg-Hua, Y., Li, W., & Davies, P. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00108 · Cited by 74
“Attempts to reduce Aβ production (130) as well as immunotherapeutic approaches to clear amyloid plaques from the brain did not show efficacy in slowing down or halting the course of AD (131, 132).”
BackgroundLiu, S., Ando, F., Fujita, Y., Liu, J., Maeda, T., Shen, X., Kikuchi, K., Matsumoto, A., Yokomori, M., Tanabe-Fujimura, C., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006420 · Cited by 57
“To reduce the levels of toxic A 42 or the A 42/A 40 ratio, many -secretase inhibitors or modulators have been designed and tested in clinical trials, but none have succeeded (3, 12).”
BackgroundGeneral practitioners’ attitudes towards early diagnosis of dementia: a cross-sectional survey
Giezendanner, S., Monsch, A. U., Kressig, R. W., Mueller, Y. K., Streit, S., Essig, S., Zeller, A., & Bally, K. (2019) · BMC Family Practice · doi:10.1186/s12875-019-0956-1 · Cited by 61
Bi, D., Yao, L., Lin, Z., Chi, L., Li, H., Xu, H. Y., Du, X., Liu, Q., Hu, Z., Lu, J., et al. (2020) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2020.117124 · Cited by 53
Alzheimer’s disease: amyloid-based pathogenesis and potential therapies
Zhou, Y., Sun, Y., Ma, Q., & Liu, Y. (2018) · Cell Stress · doi:10.15698/cst2018.07.143 · Cited by 53
“In a subsequent Phase III trial that ended in November 2016, solanezumab did not show a significant effect on slowing cognitive decline in patients mildly affected with AD [85].”
BackgroundAnti-amyloid Therapy of Alzheimer’s Disease: Current State and Prospects
Kozin, S. A., Barykin, E. P., Mitkevich, V. A., & Makarov, A. А. (2018) · Biochemistry (Moscow) · doi:10.1134/s0006297918090079 · Cited by 40
Lessons from Anti-Amyloid-β Immunotherapies in Alzheimer Disease: Aiming at a Moving Target
Wang, Y., Yan, T., Lu, H., Yin, W., Lin, B., Fan, W., Zhang, X., & Fernández-Fúnez, P. (2017) · Neurodegenerative Diseases · doi:10.1159/000478741 · Cited by 44
Li, Q., Xiong, B., Wang, Y., Lyu, W., Xing, S., Chen, Y., Liao, Q., He, S., Feng, F., Liu, W., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114510 · Cited by 35
Structure and Function of Alzheimer’s Amyloid βeta Proteins from Monomer to Fibrils: A Mini Review
Agrawal, N., & Skelton, A. A. (2019) · The Protein Journal · doi:10.1007/s10930-019-09854-3 · Cited by 24
Structure and function of therapeutic antibodies approved by the US FDA in 2023
Strohl, W. R. (2024) · Antibody Therapeutics · doi:10.1093/abt/tbae007 · Cited by 50
Targeting Infectious Agents as a Therapeutic Strategy in Alzheimer’s Disease
Fülöp, T., Munawara, U., Larbi, A., Desroches, M., Rodrigues, S., Catanzaro, M., Guidolin, A., Khalil, A., Bernier, F., Barron, A. E., et al. (2020) · CNS Drugs · doi:10.1007/s40263-020-00737-1 · Cited by 36
microRNA 155 up regulation in the CNS is strongly correlated to Down's syndrome dementia
Tili, E., Mezache, L., Michaille, J., Amann, V., Williams, J. M., Vandiver, P., Quiñónez, M., Fadda, P., Mikhail, A. A., & Nuovo, G. J. (2018) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2018.03.006 · Cited by 33
Publicising trial results before peer review
Fralick, M., & Sacks, C. A. (2019) · BMJ · doi:10.1136/bmj.l556 · Cited by 33
Self-citationSafinamide in neurological disorders and beyond: Evidence from preclinical and clinical studies
Wasan, H., Singh, D., & Kh, R. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.12.018 · Cited by 34
Yeo, I. J., Lee, M. J., Baek, A., Miller, Z. C., Bhattarai, D., Baek, Y. M., Jeong, H. J., Kim, Y. K., Kim, D., Hong, J. T., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-54846-z · Cited by 30
Paarmann, K., Prakash, S., Krohn, M., Möhle, L., Brackhan, M., Brüning, T., Eiriz, I., & Pahnke, J. (2018) · Phytomedicine · doi:10.1016/j.phymed.2018.11.033 · Cited by 30
Alginate-Derived Mannuronate Oligosaccharide Attenuates Tauopathy through Enhancing Autophagy
Bi, D., Xiao, S., Lin, Z., Yao, L., Fang, W., Wu, Y. L., Xu, H. Y., Lu, J., & Xu, X. (2021) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c00394 · Cited by 29
KDS2010: A Potent Highly Selective and Reversible MAO-B Inhibitor for Alzheimer’s Disease
Mamun, A. A., & Uddin, M. S. (2020) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207323666200117103144 · Cited by 27
Targeting Impaired Antimicrobial Immunity in the Brain for the Treatment of Alzheimer’s Disease
Fülöp, T., Tripathi, S., Rodrigues, S., Desroches, M., Bunt, T., Eiser, A. R., Bernier, F., Beauregard, P. B., Barron, A. E., Khalil, A., et al. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s264910 · Cited by 27
“decrease the Aβ load or to prevent its formation have had no effect on AD.(99,100) No cure whatsoever exists or seems to be on the horizon.”
BackgroundImpact of Genetic Risk Factors for Alzheimer’s Disease on Brain Glucose Metabolism
Cho, S., Lee, H., & Seo, J. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02297-x · Cited by 25
Lozupone, M., Dibello, V., Sardone, R., Castellana, F., Zupo, R., Lampignano, L., Bortone, I., Stallone, R., Altamura, M., Bellomo, A., et al. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2348142 · Cited by 19
“Unfortunately, in January 2017, this RCT was halted because the drug failed to meet the primary endpoint [50].”
BackgroundWaragai, M., Ho, G. J., Takamatsu, Y., Shimizu, Y., Sugino, H., Sugama, S., Takenouchi, T., Masliah, E., & Hashimoto, M. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.05.009 · Cited by 19
Imm, J. L., Kerrigan, T. L., Jeffries, A. R., & Lunnon, K. (2017) · Epigenomics · doi:10.2217/epi-2017-0076 · Cited by 14
Recent Trends in Active and Passive Immunotherapies of Alzheimer’s Disease
Alshamrani, M. (2023) · Antibodies · doi:10.3390/antib12020041 · Cited by 22
“However, other trials are still ongoing with mild AD patients (Expedition PRO), as depicted on PET imaging by the presence of positive plaques [157,158].”
BackgroundIron treatment inhibits Aβ42 deposition in vivo and reduces Aβ42/Aβ40 ratio
Shen, X., Liu, J., Fujita, Y., Liu, S., Maeda, T., Kikuchi, K., Obara, T., Takebe, A., Sayama, R., Takahashi, T., et al. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.01.119 · Cited by 10
Thambisetty, M. (2017) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00111.2017 · Cited by 8
“Even as we await readouts from pivotal clinical trials like the “Anti-Amyloid Treatment in Asymptomatic Alzheimer’s” (A4) study which will test the efficacy of A immunization using solanezumab, a monoclonal antibody to A as a disease-modifying treatment in preclinical AD (55), the recent failure of solanezumab in the…”
MethodGherasie, F.-A., Popescu, M. R., & Bartos, D. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13060944 · Cited by 16
Structure and function of therapeutic antibodies approved by the US FDA in 2025
Strohl, W. R. (2026) · Antibody Therapeutics · doi:10.1093/abt/tbag027 · Cited by 6
Alzheimer's disease: An ignored condition
Lleó, A. (2018) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2017.10.048 · Cited by 6
El Alzheimer, la enfermedad ignorada
Lleó, A. (2017) · Medicina Clínica · doi:10.1016/j.medcli.2017.10.028 · Cited by 10
Immunosenescence and Alzheimer’s Disease
Fülöp, T., Larbi, A., Khalil, A., Plotka, A., Laurent, B., Ramassamy, C., Bosco, N., Hirokawa, K., Frost, E. H., & Witkowski, J. M. (2021) · Healthy ageing and longevity · doi:10.1007/978-3-030-87532-9_9 · Cited by 5
A defense of surgical procedures regulation
Andreoletti, M., & Bina, F. (2022) · Metamedicine · doi:10.1007/s11017-022-09569-0 · Cited by 5
“Moreover, the agency performed well in protecting patients from unsafe and ineffective products [3].”
BackgroundTwenty-First Century Cures Act: Semper Vigilans
Goldstein, L. B. (2018) · Stroke · doi:10.1161/strokeaha.118.020377 · Cited by 2
“The cost of an ineffective treatment would have been the responsibility of patients, private insurers, but mostly Medicare, given the age of patients with the disease.(11) The approval might also have slowed research into other approaches.”
BackgroundUsefulness of Curcumin Analogs for the Diagnosis and Treatment of Alzheimer Disease
Farooqui, A. A., & Farooqui, T. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815461-8.00012-8 · Cited by 3
Shrestha, R. L., Parajuli, N., Chhetri, S. P., Tamang, A., Poudel, M., Shiva, M. C., Shrestha, A., Shrestha, T., Bharati, S., Maharjan, B., et al. (2026) · Advanced Theory and Simulations · doi:10.1002/adts.202502222 · Cited by 2
Approaching Regulatory Approval of Cardiovascular Regenerative Therapy
Povsic, T. J. (2018) · Circulation Research · doi:10.1161/circresaha.117.312520 · Cited by 1
“public from therapies with no therapeutic value and saved tens of billions of dollars of taxpayer expense.(9) Several approaches might accelerate clinical development,”
BackgroundA Drug Approved, Another Abandoned — Two Different Pathways for Emerging Neurologic Therapies
Shaw, G. (2017) · Neurology Today · doi:10.1097/01.nt.0000520850.89819.63
Summary and Perspective for Future Research on Dementia
Farooqui, A. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816347-4.00010-6
Complex Percutaneous Coronary Intervention: Discrete Entity or Just Another Subgroup to Analyze?
Goldsweig, A. M., & Povsic, T. J. (2021) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.121.010891
Knowledge of Dementia Treatment : Prospects for Disease-modifying Therapy in Alzheimer's Disease
Ono, K. (2021) · Japanese Journal of Neurosurgery · doi:10.7887/jcns.30.840
Munawara, U., Catanzaro, M., Xu, W., Tan, C., Hirokawa, K., Bosco, N., Dumoulin, D., Khalil, A., Larbi, A., Lévesque, S., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14821091
Munawara, U., Catanzaro, M., Xu, W., Tan, C., Hirokawa, K., Bosco, N., Dumoulin, D., Khalil, A., Larbi, A., Lévesque, S., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14821085
Munawara, U., Catanzaro, M., Xu, W., Tan, C., Hirokawa, K., Bosco, N., Dumoulin, D., Khalil, A., Larbi, A., Lévesque, S., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14821079
Munawara, U., Catanzaro, M., Xu, W., Tan, C., Hirokawa, K., Bosco, N., Dumoulin, D., Khalil, A., Larbi, A., Lévesque, S., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14821082
Poonam, Rana, R., Thakur, M., Sharma, A., Pannu, S., Sharma, S., Naman, S., Rani, S., Devi, D., Kumar, V., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1908830
Metadata
- Authors
- Sacks, C. A., Avorn, J., & Kesselheim, A. S.
- Affiliations
- Brigham and Women's Hospital (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-05-04
- Volume
- 376
- Issue
- 18
- Pages
- 1706-1708
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2611277309
- Cited by
- 55
- References
- 2
- Citations by year
- 2026: 3 · 2024: 4 · 2023: 2 · 2022: 2 · 2021: 11 · 2020: 4 · 2019: 9 · 2018: 12 · 2017: 8
- FWCI
- 6.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Healthcare Regulation
- Keywords
- solanezumab, FDA oversight, 21st Century Cures Act, drug approval, drug development costs
- MeSH terms
- Alzheimer Disease, Dementia, Humans, United States, United States Food and Drug Administration, Randomized Controlled Trials as Topic, Drug Costs, Cost Savings, Treatment Failure, Drug Approval, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.